809 related articles for article (PubMed ID: 33125511)
21. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
Hu C; Tian S; Lin L; Zhang J; Ding H
Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
[TBL] [Abstract][Full Text] [Related]
22. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of B lymphocyte infiltration in HPV
Zhang S; Wang B; Ma F; Tong F; Yan B; Liu T; Xie H; Song L; Yu S; Wei L
Cancer Sci; 2021 Apr; 112(4):1402-1416. PubMed ID: 33529452
[TBL] [Abstract][Full Text] [Related]
24. The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma.
Kunkle C; Rosado FG
Arch Pathol Lab Med; 2018 Jun; 142(6):719-720. PubMed ID: 29848031
[TBL] [Abstract][Full Text] [Related]
25. High-Grade Neuroendocrine Carcinoma of the Head and Neck: Human Papillomavirus Status and PD-L1 Expression.
Bahr K; Zimmer S; Springer E; Fottner C; Becker S; Ernst BP; Matthias C; Künzel J
ORL J Otorhinolaryngol Relat Spec; 2019; 81(5-6):309-316. PubMed ID: 31550725
[TBL] [Abstract][Full Text] [Related]
26. HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers.
Koneva LA; Zhang Y; Virani S; Hall PB; McHugh JB; Chepeha DB; Wolf GT; Carey TE; Rozek LS; Sartor MA
Mol Cancer Res; 2018 Jan; 16(1):90-102. PubMed ID: 28928286
[TBL] [Abstract][Full Text] [Related]
27. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
Messerschmidt C; Obermayer B; Klinghammer K; Ochsenreither S; Treue D; Stenzinger A; Glimm H; Fröhling S; Kindler T; Brandts CH; Schulze-Osthoff K; Weichert W; Tinhofer I; Klauschen F; Keilholz U; Beule D; Rieke DT
Int J Cancer; 2020 Oct; 147(8):2293-2302. PubMed ID: 32468570
[TBL] [Abstract][Full Text] [Related]
28. Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer.
Badr M; Jöhrens K; Allgäuer M; Boxberg M; Weichert W; Tinhofer I; Denkert C; Schirmacher P; Stenzinger A; Budczies J
Cancer Immunol Immunother; 2019 Sep; 68(9):1443-1454. PubMed ID: 31444607
[TBL] [Abstract][Full Text] [Related]
29. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.
Lyford-Pike S; Peng S; Young GD; Taube JM; Westra WH; Akpeng B; Bruno TC; Richmon JD; Wang H; Bishop JA; Chen L; Drake CG; Topalian SL; Pardoll DM; Pai SI
Cancer Res; 2013 Mar; 73(6):1733-41. PubMed ID: 23288508
[TBL] [Abstract][Full Text] [Related]
30. Immune gene expression in head and neck squamous cell carcinoma patients.
Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
[TBL] [Abstract][Full Text] [Related]
31. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
Chen SW; Li SH; Shi DB; Jiang WM; Song M; Yang AK; Li YD; Bei JX; Chen WK; Zhang Q
Int J Biol Markers; 2019 Dec; 34(4):398-405. PubMed ID: 31674884
[TBL] [Abstract][Full Text] [Related]
32. PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.
Riva G; Pecorari G; Biolatti M; Pautasso S; Lo Cigno I; Garzaro M; Dell'Oste V; Landolfo S
Mol Biol Rep; 2019 Jun; 46(3):3333-3347. PubMed ID: 30980272
[TBL] [Abstract][Full Text] [Related]
33. Functional HPV-specific PD-1
Eberhardt CS; Kissick HT; Patel MR; Cardenas MA; Prokhnevska N; Obeng RC; Nasti TH; Griffith CC; Im SJ; Wang X; Shin DM; Carrington M; Chen ZG; Sidney J; Sette A; Saba NF; Wieland A; Ahmed R
Nature; 2021 Sep; 597(7875):279-284. PubMed ID: 34471285
[TBL] [Abstract][Full Text] [Related]
34. [Current events in immunotherapy for upper aerodigestive tract cancer].
Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
[TBL] [Abstract][Full Text] [Related]
36. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
[TBL] [Abstract][Full Text] [Related]
37. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
[TBL] [Abstract][Full Text] [Related]
38. Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status.
Gangkofner DS; Holzinger D; Schroeder L; Eichmüller SB; Zörnig I; Jäger D; Wichmann G; Dietz A; Broglie MA; Herold-Mende C; Dyckhoff G; Boscolo-Rizzo P; Ezic J; Marienfeld RB; Möller P; Völkel G; Kraus JM; Kestler HA; Brunner C; Schuler PJ; Wigand M; Theodoraki MN; Doescher J; Hoffmann TK; Pawlita M; Butt J; Waterboer T; Laban S
Int J Cancer; 2019 Dec; 145(12):3436-3444. PubMed ID: 31407331
[TBL] [Abstract][Full Text] [Related]
39. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
[TBL] [Abstract][Full Text] [Related]
40. PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.
Nagarajan P; El-Hadad C; Gruschkus SK; Ning J; Hudgens CW; Sagiv O; Gross N; Tetzlaff MT; Esmaeli B
Invest Ophthalmol Vis Sci; 2019 May; 60(6):2388-2398. PubMed ID: 31141610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]